Tempest Therapeutics Inc (TPST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has a cash flow conversion efficiency ratio of -9.243x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.60 Million) by net assets ($822.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TPST market cap for the company's overall valuation and market capitalisation.
Tempest Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Tempest Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tempest Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tempest Therapeutics Inc ranked by their cash flow conversion efficiency. See Tempest Therapeutics Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INOVIQ LTD.
F:EGQ0
|
N/A |
|
Horseshoe Metals Ltd
AU:HOR
|
0.151x |
|
COSMOS HEALTH NEW DL-01
F:V67A
|
-0.249x |
|
Mr. Onion
TWO:2740
|
0.069x |
|
Hanan Mor
TA:HNMR
|
0.062x |
|
Chibougamau Independent Mines Inc
V:CBG
|
0.012x |
|
Wave Entertainment Public Company Limited
BK:WAVE
|
0.054x |
|
Dev Information Technology Limited
NSE:DEVIT
|
0.054x |
Annual Cash Flow Conversion Efficiency for Tempest Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Tempest Therapeutics Inc from 2012 to 2025. View Tempest Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.67 Million | $-26.82 Million | -4.022x | -132.93% |
| 2024-12-31 | $19.13 Million | $-33.03 Million | -1.727x | -68.96% |
| 2023-12-31 | $26.77 Million | $-27.36 Million | -1.022x | +40.43% |
| 2022-12-31 | $18.11 Million | $-31.07 Million | -1.716x | -138.72% |
| 2021-12-31 | $36.12 Million | $-25.96 Million | -0.719x | -359.98% |
| 2020-12-31 | $-68.79 Million | $-19.02 Million | 0.276x | +140.15% |
| 2019-12-31 | $59.87 Million | $-41.22 Million | -0.689x | -112.90% |
| 2018-12-31 | $73.12 Million | $-23.65 Million | -0.323x | +76.18% |
| 2017-12-31 | $14.98 Million | $-20.34 Million | -1.358x | -137.97% |
| 2016-12-31 | $108.22 Million | $-61.73 Million | -0.570x | -43.90% |
| 2015-12-31 | $126.85 Million | $-50.29 Million | -0.396x | +28.30% |
| 2014-12-31 | $55.33 Million | $-30.59 Million | -0.553x | -27.42% |
| 2013-12-31 | $41.70 Million | $-18.09 Million | -0.434x | -19.49% |
| 2012-12-31 | $30.72 Million | $-11.16 Million | -0.363x | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more